Related Experiment Videos
Do leukemia patients with chromosome 16 inversion--inv(16)(p13q22)--have a rare fragile site at 16q22?
K Ohyashiki1, J H Ohyashiki, K Toyama
1Department of Internal Medicine, Tokyo Medical College, Japan.
Abstract:
Chromosomes were examined in the peripheral blood cells from three cases of acute myelomonocytic leukemia (AMMoL) with inv(16)(p13q22) in order to induce the rare fragile site at 16q22 [fra(16)(q22)] with distamycin-A and berenil. No chromosomal gaps, breaks, or reaRrangements at 16q22 were noted in lymphocytes treated from these cases, indicating that AMMoL patients with inv(16)(p13q22) do not always have the rare fragile site FRA16B, FRA(16)(q22). A predisposition to neoplasia in carriers of this fragile site is questionable.
Insights
This study investigated the fragile site FRA16B in acute myelomonocytic leukemia (AMMoL) patients with inv(16)(p13q22). The rare fragile site was not consistently found, questioning its link to neoplasia.
Area of Science:
- Cytogenetics
- Hematology
- Oncology
Background:
- Acute myelomonocytic leukemia (AMMoL) is a subtype of myeloid leukemia.
- The inversion 16 (inv(16)(p13q22)) is a recurrent chromosomal abnormality in AMMoL.
- The fragile site FRA16B at 16q22 has been associated with certain cancers.
Purpose of the Study:
- To investigate the presence and inducibility of the fragile site FRA16B (16q22) in patients with AMMoL and inv(16)(p13q22).
- To determine if AMMoL patients with inv(16)(p13q22) consistently harbor the FRA16B fragile site.
Main Methods:
- Peripheral blood cells from three AMMoL patients with inv(16)(p13q22) were analyzed.
- Chromosomal fragility at 16q22 was induced using distamycin-A and berenil.
- Lymphocytes were examined for gaps, breaks, or rearrangements at 16q22.
Main Results:
- No chromosomal gaps, breaks, or rearrangements were observed at 16q22 in the treated lymphocytes.
- The fragile site FRA16B was not consistently induced in AMMoL patients with inv(16)(p13q22).
Conclusions:
- AMMoL patients with inv(16)(p13q22) do not necessarily possess the rare fragile site FRA16B.
- The predisposition to neoplasia in carriers of FRA16B is questionable in the context of AMMoL with inv(16).